Mink Therapeutics IncNASDAQ:INKTNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.9275
- TODAY'S CHANGE (%)0.0563 (6.4624%)
- Bid / Lots0.8975/ 5
- Ask / Lots0.9749/ 6
- Open / Previous Close0.9000 / 0.8712
- Day Range
- 52 Week Range
- Volume32,317
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INKT |
|---|---|---|
| 09:32 ET | 334 | 0.9 |
| 09:41 ET | 1000 | 0.88115 |
| 09:50 ET | 750 | 0.8819 |
| 10:50 ET | 100 | 0.921969 |
| 11:20 ET | 3066 | 0.928 |
| 11:22 ET | 2000 | 0.91675 |
| 11:27 ET | 334 | 0.912 |
| 11:58 ET | 100 | 0.925 |
| 12:12 ET | 357 | 0.9159 |
| 12:23 ET | 456 | 0.9085 |
| 12:32 ET | 5740 | 0.919999 |
| 12:36 ET | 1998 | 0.91105 |
| 12:50 ET | 118 | 0.911051 |
| 12:54 ET | 3568 | 0.9289 |
| 12:56 ET | 800 | 0.913549 |
| 01:19 ET | 178 | 0.9 |
| 01:33 ET | 274 | 0.9 |
| 01:51 ET | 1314 | 0.91395 |
| 02:31 ET | 109 | 0.91425 |
| 03:05 ET | 350 | 0.91425 |
| 03:36 ET | 846 | 0.9275 |
| 03:52 ET | 1000 | 0.9142 |
| 03:59 ET | 2287 | 0.9275 |
Apr 8, 2024
DJ MiNK Therapeutics' MiNK-215 Data Show Potential Treatment for Liver Metastases, from 12:23PM ET on Monday Apr 08, 2024 by Dow Jones
12:23PM ET on Monday Apr 08, 2024 by Dow JonesMiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR, from 12:00PM ET on Monday Apr 08, 2024 by Dow Jones
12:00PM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mink Therapeutics Inc | 30.2M | -1.4x | --- |
Achilles Therapeutics PLC | 30.9M | -0.4x | --- |
Vicapsys Life Sciences Inc | 31.4M | -29.9x | --- |
Acurx Pharmaceuticals Inc | 31.8M | -1.8x | --- |
LianBio | 32.2M | -0.3x | --- |
Nymox Pharmaceutical Corp | 28.0M | -5.6x | --- |
Company Information
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Contact Information
- Headquarters
- 149 Fifth Avenue, Suite 500NEW YORK, NY, United States 10010
- Phone
- 212-994-8250
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Garo Armen
- President, Chief Executive Officer, Director
- Jennifer Buell
- Chief Scientific Officer
- Marc Van Dijk
- Treasurer
- Christine Klaskin
- Independent Director
- Peter Behner
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 34.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.65 |
Book Value | $-0.52 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
